BR112023002626A2 - Novos compostos tendo atividade inibitória sobre o receptor de prostaglandina e2 e usos dos mesmos - Google Patents
Novos compostos tendo atividade inibitória sobre o receptor de prostaglandina e2 e usos dos mesmosInfo
- Publication number
- BR112023002626A2 BR112023002626A2 BR112023002626A BR112023002626A BR112023002626A2 BR 112023002626 A2 BR112023002626 A2 BR 112023002626A2 BR 112023002626 A BR112023002626 A BR 112023002626A BR 112023002626 A BR112023002626 A BR 112023002626A BR 112023002626 A2 BR112023002626 A2 BR 112023002626A2
- Authority
- BR
- Brazil
- Prior art keywords
- prostaglandin
- receptor
- inhibitory activity
- new compounds
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000008866 Prostaglandin E receptors Human genes 0.000 title abstract 3
- 108010088540 Prostaglandin E receptors Proteins 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
NOVOS COMPOSTOS TENDO ATIVIDADE INIBITÓRIA SOBRE O RECEPTOR DE PROSTAGLANDINA E2 E USOS DOS MESMOS. O presente pedido se refere a um novo composto tendo atividade inibitória sobre o receptor de prostaglandina E2 e usos do mesmo, e fornece um composto representado pela fórmula I, um solvato, estereoisômero ou sal farmaceuticamente aceitável do mesmo, uma composição farmacêutica compreendendo o mesmo, e um método de uso do mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200105545 | 2020-08-21 | ||
PCT/KR2021/011143 WO2022039563A1 (en) | 2020-08-21 | 2021-08-20 | Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023002626A2 true BR112023002626A2 (pt) | 2023-04-04 |
Family
ID=80322868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023002626A BR112023002626A2 (pt) | 2020-08-21 | 2021-08-20 | Novos compostos tendo atividade inibitória sobre o receptor de prostaglandina e2 e usos dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230365582A1 (pt) |
EP (1) | EP4200291A4 (pt) |
JP (1) | JP2023537909A (pt) |
KR (1) | KR20220023730A (pt) |
CN (1) | CN116529238A (pt) |
AU (1) | AU2021327622B2 (pt) |
BR (1) | BR112023002626A2 (pt) |
CA (1) | CA3191456A1 (pt) |
CL (1) | CL2023000339A1 (pt) |
CO (1) | CO2023003420A2 (pt) |
IL (1) | IL300774A (pt) |
MX (1) | MX2023002068A (pt) |
WO (1) | WO2022039563A1 (pt) |
ZA (1) | ZA202302554B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2023220699A1 (en) * | 2022-02-15 | 2024-08-29 | Kanaph Therapeutics Inc. | Pharmaceutical composition for treating cancer comprising novel compounds for inhibiting prostaglandin e2 receptor and anticancer drug |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013517295A (ja) * | 2010-01-19 | 2013-05-16 | セラヴァンス, インコーポレーテッド | 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬 |
LT2861566T (lt) * | 2012-06-13 | 2017-02-10 | F. Hoffmann-La Roche Ag | Nauji diazaspirocikloalkanai ir azaspirocikloalkanai |
US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
JO3581B1 (ar) * | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
-
2021
- 2021-08-20 IL IL300774A patent/IL300774A/en unknown
- 2021-08-20 JP JP2023507917A patent/JP2023537909A/ja active Pending
- 2021-08-20 CA CA3191456A patent/CA3191456A1/en active Pending
- 2021-08-20 CN CN202180072005.3A patent/CN116529238A/zh active Pending
- 2021-08-20 US US18/042,352 patent/US20230365582A1/en active Pending
- 2021-08-20 EP EP21858650.1A patent/EP4200291A4/en active Pending
- 2021-08-20 BR BR112023002626A patent/BR112023002626A2/pt unknown
- 2021-08-20 KR KR1020210110489A patent/KR20220023730A/ko not_active Application Discontinuation
- 2021-08-20 AU AU2021327622A patent/AU2021327622B2/en active Active
- 2021-08-20 MX MX2023002068A patent/MX2023002068A/es unknown
- 2021-08-20 WO PCT/KR2021/011143 patent/WO2022039563A1/en active Application Filing
-
2023
- 2023-02-02 CL CL2023000339A patent/CL2023000339A1/es unknown
- 2023-02-24 ZA ZA2023/02554A patent/ZA202302554B/en unknown
- 2023-03-21 CO CONC2023/0003420A patent/CO2023003420A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021327622B2 (en) | 2024-03-07 |
AU2021327622A1 (en) | 2023-03-02 |
KR20220023730A (ko) | 2022-03-02 |
MX2023002068A (es) | 2023-03-17 |
TW202211917A (zh) | 2022-04-01 |
CO2023003420A2 (es) | 2023-04-17 |
CA3191456A1 (en) | 2022-02-24 |
CL2023000339A1 (es) | 2023-08-18 |
ZA202302554B (en) | 2024-06-26 |
EP4200291A4 (en) | 2024-09-25 |
US20230365582A1 (en) | 2023-11-16 |
CN116529238A (zh) | 2023-08-01 |
IL300774A (en) | 2023-04-01 |
JP2023537909A (ja) | 2023-09-06 |
WO2022039563A1 (en) | 2022-02-24 |
EP4200291A1 (en) | 2023-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
BR112022012385A2 (pt) | Método de preparação e aplicação de composto de agente de degradação de proteínas | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
BR112023003832A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
EA202092159A1 (ru) | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение | |
BR112023002626A2 (pt) | Novos compostos tendo atividade inibitória sobre o receptor de prostaglandina e2 e usos dos mesmos | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
MX2022003830A (es) | Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo. | |
AR043186A1 (es) | Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende |